Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8273 vs erlotinib or gefitinib in first-line EGFR‑mutant stage IIIB/IV NSCLC
2015-002894-39Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naquotinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Progression-free survival (PFS) by independent radiologic review. Started Sep 2015; status: completed.
02
Drugs
naquotinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2015-002894-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002894-39.